StockData
Adaptive Biotechnologies Corp logo

Adaptive Biotechnologies Corp (ADPT) stock

ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30
$28.49+0.62 (+2.22%)

Close on Nov 17, 2026Market cap $4.55BP/E –Yield –

Earnings

Adaptive Biotechnologies's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 4, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$83.90M
-10.7% on a year earlier
EPS, Q3 FY2026
$0.02
Latest guidance
Raised
Nov 4, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Adaptive Biotechnologies's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 4, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$83.90M-10.7%$0.02Release
Q2 FY2026ended Jun 30, 2026Jul 29, 2026after the close$71.60M+21.6%–Release
Q1 FY2026ended Mar 31, 2026May 5, 2026after the close$70.90M+35.3%–Release
Q4 FY2025ended Dec 31, 2025Feb 5, 2026after the close$71.70M+50.9%-$0.09Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025after the close$94.00M+102.6%–Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025after the close$58.90M+36.3%–Release
Q1 FY2025ended Mar 31, 2025May 1, 2025after the close$52.40M+25.1%-$0.20Release
Q4 FY2024ended Dec 31, 2024Feb 11, 2025after the close$47.50M+3.7%–Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024after the close$46.40M+22.4%–Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024after the close$43.20M-11.7%-$0.31Release
Q1 FY2024ended Mar 31, 2024May 7, 2024after the close$41.90M+11.4%-$0.33Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Adaptive Biotechnologies's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
MRD revenueFY2026$268.00M – $278.00M$260.00M – $270.00MRaisedJul 29, 2026
revenue for the MRD businessFY2026$276.00M – $286.00M$255.00M – $265.00MRaisedNov 4, 2026
MRD revenue annual growthFY2026+26% – +31%–NewJul 29, 2026
total company operating expenses, including cost of revenueFY2026$350.00M$350.00M – $360.00MLoweredNov 4, 2026
total company operating expenses, including cost of revenueFY2026$350.00M – $355.00M$350.00M – $360.00MLoweredJul 29, 2026

Guidance vs results

The last range Adaptive Biotechnologies gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$202.00M – $207.00M$277.00MΣ4QAbove range

Guidance history

Every forecast Adaptive Biotechnologies put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026total company operating expenses, including cost of revenueFY2026$350.00MLowered
Nov 4, 2026revenue for the MRD businessFY2026$276.00M – $286.00MRaised
Jul 29, 2026MRD revenue annual growthFY2026+26% – +31%New
Jul 29, 2026total company operating expenses, including cost of revenueFY2026$350.00M – $355.00MLowered
Jul 29, 2026MRD revenueFY2026$268.00M – $278.00MRaised
May 5, 2026total company operating expenses, including cost of revenueFY2026$350.00M – $360.00MNew
May 5, 2026revenue for the MRD businessFY2026$260.00M – $270.00MNew
Feb 5, 2026total company operating expenses, including cost of revenueFY2026$350.00M – $360.00MNew
Feb 5, 2026revenue for the MRD businessFY2026$255.00M – $265.00MNew
Nov 5, 2025operating expenses, including cost of revenueFY2025$335.00M – $340.00MNew
Nov 5, 2025total company cash burnFY2025$45.00M – $50.00MLowered
Nov 5, 2025full year revenue for the MRD businessFY2025$202.00M – $207.00MNew
Aug 5, 2025total company operating expenses, including cost of revenueFY2025$335.00M – $345.00MRaised
Aug 5, 2025total company cash burnFY2025$45.00M – $55.00MLowered
Aug 5, 2025revenue for the MRD businessFY2025$190.00M – $200.00MRaised
May 1, 2025total company operating expenses, including cost of revenueFY2025$335.00M – $345.00MRaised
May 1, 2025total company cash burnFY2025$50.00M – $60.00MLowered
May 1, 2025revenue for the MRD businessFY2025$180.00M – $190.00MRaised
Feb 11, 2025total company operating expenses, including cost of revenueFY2025$340.00M – $350.00MNew
Feb 11, 2025total company cash burnFY2025$60.00M – $70.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Adaptive Biotechnologies filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. News
  4. News
  5. News
  6. News
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?